期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 91, 期 6, 页码 557-560出版社
WILEY-BLACKWELL
DOI: 10.1111/ejh.12186
关键词
acute myeloid leukaemia; ataxia telangiectasia; reduced-dose chemotherapy
类别
资金
- Grants-in-Aid for Scientific Research [24591539] Funding Source: KAKEN
Ataxia telangiectasia (AT) is a rare autosomal recessive multisystem disorder characterised by cerebellar degeneration, immunodeficiency and cancer predisposition. Around 10% of AT patients develop lymphoid malignancies, but the development of myeloid leukaemia with AT (AT-AML) is extremely rare, and there have been no previous publications regarding suitable therapies. Here, we first describe a successful therapeutic experience in a patient with AT-AML (FAB-M1) who attained remission after induction therapy and maintained stable disease for a year. To minimise therapy-induced toxicity, low-dose induction was applied first, though this was obviously insufficient and the patient subsequently responded well to dose-intensified short-term chemotherapy. In this report, we suggest a curative therapeutic approach for AT-AML, though the issue of how best to manage patients with cancer complicated by immunodeficiency remains undecided.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据